# Variant Interpretation for Cancer (VIC): a computational tool for assessing clinical impacts of somatic variants

**Authors:** Max M. He, Quan Li, Muqing Yan, Hui Cao, Yue Hu, Karen Y. He, Kajia Cao, Marilyn M. Li, Kai Wang

PMC · DOI: 10.1186/s13073-019-0664-4 · Genome Medicine · 2019-08-23

## TL;DR

The paper introduces VIC, a tool that helps labs classify cancer-related genetic variants more efficiently and consistently.

## Contribution

VIC is a semi-automated tool that streamlines somatic variant interpretation using standardized guidelines with customizable settings.

## Key findings

- VIC is time-efficient and conservative in classifying variants with strong clinical significance.
- VIC was tested on cancer-panel datasets and shown to support manual interpretation effectively.
- The tool can be customized for integration into clinical pipelines.

## Abstract

Clinical laboratories implement a variety of measures to classify somatic sequence variants and identify clinically significant variants to facilitate the implementation of precision medicine. To standardize the interpretation process, the Association for Molecular Pathology (AMP), American Society of Clinical Oncology (ASCO), and College of American Pathologists (CAP) published guidelines for the interpretation and reporting of sequence variants in cancer in 2017. These guidelines classify somatic variants using a four-tiered system with ten criteria. Even with the standardized guidelines, assessing clinical impacts of somatic variants remains to be tedious. Additionally, manual implementation of the guidelines may vary among professionals and may lack reproducibility when the supporting evidence is not documented in a consistent manner.

We developed a semi-automated tool called “Variant Interpretation for Cancer” (VIC) to accelerate the interpretation process and minimize individual biases. VIC takes pre-annotated files and automatically classifies sequence variants based on several criteria, with the ability for users to integrate additional evidence to optimize the interpretation on clinical impacts. We evaluated VIC using several publicly available databases and compared with several predictive software programs. We found that VIC is time-efficient and conservative in classifying somatic variants under default settings, especially for variants with strong and/or potential clinical significance. Additionally, we also tested VIC on two cancer-panel sequencing datasets to show its effectiveness in facilitating manual interpretation of somatic variants.

Although VIC cannot replace human reviewers, it will accelerate the interpretation process on somatic variants. VIC can also be customized by clinical laboratories to fit into their analytical pipelines to facilitate the laborious process of somatic variant interpretation. VIC is freely available at https://github.com/HGLab/VIC/.

The online version of this article (10.1186/s13073-019-0664-4) contains supplementary material, which is available to authorized users.

## Full-text entities

- **Genes:** TXK (TXK tyrosine kinase) [NCBI Gene 7294] {aka BTKL, PSCTK5, PTK4, RLK, TKL}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, DPYD (dihydropyrimidine dehydrogenase) [NCBI Gene 1806] {aka DHP, DHPDHASE, DPD, DYPD}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, FBXW7 (F-box and WD repeat domain containing 7) [NCBI Gene 55294] {aka AGO, CDC4, DEDHIL, FBW6, FBW7, FBX30}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, BRAF (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 673] {aka B-RAF1, B-raf, BRAF-1, BRAF1, NS7, RAFB1}, PTPRU (protein tyrosine phosphatase receptor type U) [NCBI Gene 10076] {aka FMI, PCP-2, PTP, PTP-J, PTP-PI, PTP-RO}, PABPC1 (poly(A) binding protein cytoplasmic 1) [NCBI Gene 26986] {aka PAB1, PABP, PABP1, PABPC2, PABPL1}
- **Diseases:** NSCLC (MESH:D002289), CIViC (MESH:D009369), leukemia (MESH:D007938), LoF-intolerant (MESH:D006315), CAP (MESH:D006478), carcinogenesis (MESH:D063646), bladder carcinoma (MESH:D001749), chronic lymphocytic leukemia (MESH:D015451), lung cancer (MESH:D008175), VAF (MESH:D006316), toxicity (MESH:D064420), Melanoma (MESH:D008545), chronic-myeloid-leukemia (MESH:D015464), colorectal cancers (MESH:D015179), ASCO (MESH:C000719191),  (MESH:D020022)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** c.261delC, rs3918290, p.E770delinsEAYVM, 97915614-97915614 C>T, rs28934571, -153249393 G>T, p.R678Q, c.2310_2311ins GCATACGTGATG, -55259515T> G, c.962C>T, G>A
- **Cell lines:** PolyPhen-2 — Homo sapiens (Human), Colon carcinoma, Cancer cell line (CVCL_A628), COSMIC — Drosophila melanogaster (Fruit fly), Spontaneously immortalized cell line (CVCL_IY73)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC6708137/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC6708137/full.md

## References

32 references — full list in the complete paper: https://tomesphere.com/paper/PMC6708137/full.md

---
Source: https://tomesphere.com/paper/PMC6708137